Burkitt Lymphoma: all 407 studies
Page 2 of 5. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.
- Study of Out of Specification for TisagenlecleucelRecruitingNCT04094311Phase 3
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingNCT03959085Phase 3
- REal World Data in LYmphoma and Survival in AdultsRecruitingNCT03869619
- CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCTRecruitingNCT03810196Not applicable
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingNCT03739814Phase 2
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT03666000Phase 1
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingNCT03595917Phase 1
- Long-term Follow-up Study of Patients Receiving CAR-T CellsRecruitingNCT03375619
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingNCT03150693Phase 3
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaRecruitingNCT03136146Phase 2
- Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaRecruitingNCT02877303Phase 2
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLRecruitingNCT02393157Phase 2
- Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaRecruitingNCT01371630Phase 1/2
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Study of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesTerminatedNCT05537766Phase 2Results posted
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaTerminatedNCT05255601Phase 1/2Results posted
- Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT05032183Phase 1/2Results posted
- Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell LymphomasTerminatedNCT04933617Phase 1Results posted
- Besponsa Post Marketing Surveillance StudyCompletedNCT04307134Results posted
- Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
- A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)TerminatedNCT04035434Phase 1/2Results posted
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell TransplantationTerminatedNCT03856216Phase 2Results posted
- Mobile Health Case Management System for Reducing Pediatric Treatment AbandonmentCompletedNCT03677128Not applicableResults posted
- Trial Evaluating MGTA-456 in Patients With High-Risk MalignancyActive, not recruitingNCT03674411Phase 2Results posted
- Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT03504644Phase 1/2Results posted
- Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaTerminatedNCT03488225Phase 2Results posted
- Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow LymphoblastsCompletedNCT03160079Phase 1/2Results posted
- Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasActive, not recruitingNCT03038672Phase 2Results posted
- Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic LeukemiaCompletedNCT02997761Phase 2Results posted
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsCompletedNCT02883049Phase 3Results posted
- Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaActive, not recruitingNCT02879695Phase 1Results posted
- Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell TransplantActive, not recruitingNCT02797470Phase 1/2Results posted
- UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
- Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)CompletedNCT02669017Phase 1Results posted
- Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell MalignanciesTerminatedNCT02483000Phase 1Results posted
- Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT02481310Phase 1/2Results posted
- Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual DiseaseCompletedNCT02458014Phase 2Results posted
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
- Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02199184Phase 2Results posted
- Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesTerminatedNCT02145039Not applicableResults posted
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT02143414Phase 2Results posted
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT02101853Phase 3Results posted
- Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT02037256Not applicableResults posted
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic LeukemiaActive, not recruitingNCT02003222Phase 3Results posted
- Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01947140Phase 1/2Results posted
- S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01925131Phase 1Results posted
- Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
- Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT01812005Phase 2Results posted
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
- A Phase I Trial of AZD3965 in Patients With Advanced CancerCompletedNCT01791595Phase 1Results posted
- Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
- Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
- Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/LymphomaTerminatedNCT01685606Phase 2Results posted
- Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 1Results posted
- Double Cord Versus Haploidentical (BMT CTN 1101)CompletedNCT01597778Phase 3Results posted
- Rasburicase and Allopurinol in Treating Patients With Hematologic MalignanciesTerminatedNCT01564277Phase 2Results posted
- Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
- Safety and Tolerability of HSC835 in Patients With Hematological MalignanciesCompletedNCT01474681Phase 1/2Results posted
- High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTerminatedNCT01434472Phase 2Results posted
- Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
- Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted
- Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT01408043Not applicableResults posted
- MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- VincristineCompletedNCT01397825Phase 1/2Results posted
- Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT01363128Phase 2Results posted
- Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
- Imexon for Relapsed Follicular and Aggressive LymphomasCompletedNCT01314014Phase 2Results posted
- Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
- Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic CancerCompletedNCT01233921Not applicableResults posted
- A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD ChemotherapyCompletedNCT01184885Early Phase 1Results posted
- Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
- CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)CompletedNCT01134575Phase 2Results posted
- Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2Results posted
- Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01109069Phase 2Results posted
- Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
- Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell LymphomaCompletedNCT01092182Phase 2Results posted
- Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01076270Not applicableResults posted
- Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
- Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic CancerTerminatedNCT01044745Phase 2Results posted
- Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01028716Phase 2Results posted
- Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell LymphomaCompletedNCT00867529Phase 2Results posted
- Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)CompletedNCT00864227Phase 2Results posted
- Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
- Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)CompletedNCT00849147Phase 2Results posted
- Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's LymphomaCompletedNCT00807495Phase 2Results posted
- Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT00792948Phase 2Results posted
- Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseCompletedNCT00719888Phase 2Results posted
- Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaCompletedNCT00669877Phase 2Results posted
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
- High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
- Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia PatientsCompletedNCT00412243Phase 1/2Results posted
- Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
- Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like LymphomaCompletedNCT00392990Phase 2Results posted